Lupin Pharma

  • Pharma Major Lupin Limited (Lupin) announced  that it has received final approval for its Blisovi 24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market a generic version of Warner Chilcott's Loestrin®24 Fe Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg). Lupin’s US subsidiary, Lupin Pharmaceuticals Inc. would commence promoting the product shortly in the US.

  • Lupin Pharmaceuticals Inc, a subsidiary of the company, has launched calcium acetate capsules having received final approval from the US health regulator. The drug is indicated for the control of hyperphosphatemia in end stage renal failure.

  • Mumbai based pharma major Lupin Limited announced that its subsidiary Lupin Pharmaceuticals Inc (Lupin) has launched its Duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength.

  • Lupin, India's fifth largest drug maker, announced the acquisition of Russia's Biocom, a fast-growing generic pharmaceuticals firm, for an undisclosed amount.
    Lupin Chief Executive Officer, Vinita Gupta, said: "We are excited about our entry into the Russian market through Biocom. Russia is an attractive market and this acquisition will also enable our expansion into neighbouring markets as well as other Eastern European markets in the future."

  • 23 April 2015
    Lupin introduce Zaxine in Canada for liver disease treatment

    Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.

  • (11th November, 2014); Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Celecoxib Capsules, 50 mg from the United States Food and Drugs Administration (FDA) to market a generic version of G.D. Searle LLC’s (a subsidiary of Pfizer Inc.) Celebrex® Capsules 50 mg. Lupin also received tentative approvals for its Celecoxib capsules 100 mg, 200 mg and 400 mg strengths from the FDA.

  • 9 April 2012
    Work as Sr. Executive-Process Development in Lupin Pharmaceuticals

    Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc.

  • 13 March 2012
    Freshers invited for Walk in Interview for the post of Marketing Trainees/Executive and Medical Representative in Lupin Pharma

    Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company today has significant market share in key markets in the Cardiovascular, Diabctology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments.

  • 12 January 2012
    Require Officer Quality Control with Pharma API & Bulk Drugs in Lupin Pharma - 5 vacancies

  • 16 November 2011
    Walk in @ Lupin Pharma | Apply for Jr. Officer/Officer - Production, Officer/Executive -QA/QC

    Lupin Pharmaceuticals, Inc. is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top six pharmaceutical companies in India. Through our sales and marketing headquarters in Baltimore, MD, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies.

Subscribe to Lupin Pharma